Frontiers in immunology · 2026
An integrated immunopathological model of syphilis serofast: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeng Yong-Xin, Yang Lin, He Yuan-Yuan, Deng Zi-Liang, Ke Wu-Jian, Wang Hai-Ying
Аннотация
OBJECTIVE: The immunological mechanisms underlying the syphilis serofast remain incompletely elucidated. This systematic review and meta-analysis aims to quantify the association between key immune indicators and serofast.
METHODS: We systematically searched PubMed, Embase, Web of Science, Google Scholar and Chinese databases (CNKI, VIP, and CBMdisc) until December 31, 2024, for case-control, cross-sectional or cohort studies meeting serofast criteria (RPR/TRUST titer ≤1:8 persisting for ≥12 months). Random-effects models were used to calculate standardized mean differences (SMD) with 95% confidence intervals (CIs). The risk of bias was assessed using the Newcastle-Ottawa Scale (for observational studies) by two independent reviewers.
RESULTS: A total of 38 studies involving 5082 patients were included. The serofast group exhibited significant immune dysregulation: (1) Cellular immune suppression:decreased CD4+ T cells (SMD=-0.61, I²=33.5%) and increased CD8+ T cells (SMD = 0.40, I²=66.7%), leading to an inverted CD4+/CD8+ ratio (SMD=-0.44, I²=64.7%); (2) Th1/Th2 shift:suppression of Th1 cytokines (e.g., IFN-γ, SMD=-2.19, I²=95.7%) with a predominant Th2 response (e.g., IL-10, SMD =+ 2.63,I²=92.5%); (3) Humoral abnormalities: persistently elevated IgM (SMD = 0.96,I²=94.4%) and complement consumption (C3,SMD=-0.60, I²=89.0%; C4, SMD=-0.80, I²=87.6%); (4) Signaling dysregulation: downregulated TLR2 expression and disordered chemokine receptors (TLR2 mRNA,SMD=-1.52, I²=36.0%).The substantial heterogeneity (I² > 50%) observed in several analyses was explored in subgroup and sensitivity analyses, as detailed in the main text.
CONCLUSIONS: The serofast is characterized by a cascade of "cellular immune suppression-Th1/Th2 shift-complement exhaustion." Our findings establish a quantified immunological basis for the serofast state and suggest potential targets for immunomodulatory therapy.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420251156478.
METHODS: We systematically searched PubMed, Embase, Web of Science, Google Scholar and Chinese databases (CNKI, VIP, and CBMdisc) until December 31, 2024, for case-control, cross-sectional or cohort studies meeting serofast criteria (RPR/TRUST titer ≤1:8 persisting for ≥12 months). Random-effects models were used to calculate standardized mean differences (SMD) with 95% confidence intervals (CIs). The risk of bias was assessed using the Newcastle-Ottawa Scale (for observational studies) by two independent reviewers.
RESULTS: A total of 38 studies involving 5082 patients were included. The serofast group exhibited significant immune dysregulation: (1) Cellular immune suppression:decreased CD4+ T cells (SMD=-0.61, I²=33.5%) and increased CD8+ T cells (SMD = 0.40, I²=66.7%), leading to an inverted CD4+/CD8+ ratio (SMD=-0.44, I²=64.7%); (2) Th1/Th2 shift:suppression of Th1 cytokines (e.g., IFN-γ, SMD=-2.19, I²=95.7%) with a predominant Th2 response (e.g., IL-10, SMD =+ 2.63,I²=92.5%); (3) Humoral abnormalities: persistently elevated IgM (SMD = 0.96,I²=94.4%) and complement consumption (C3,SMD=-0.60, I²=89.0%; C4, SMD=-0.80, I²=87.6%); (4) Signaling dysregulation: downregulated TLR2 expression and disordered chemokine receptors (TLR2 mRNA,SMD=-1.52, I²=36.0%).The substantial heterogeneity (I² > 50%) observed in several analyses was explored in subgroup and sensitivity analyses, as detailed in the main text.
CONCLUSIONS: The serofast is characterized by a cascade of "cellular immune suppression-Th1/Th2 shift-complement exhaustion." Our findings establish a quantified immunological basis for the serofast state and suggest potential targets for immunomodulatory therapy.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420251156478.